Skip to main content
Terminated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

By April 24, 2017No Comments

Condition

Mesothelioma

Estimated Enrollment: 13

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: MCC-14896|AVF3483s

Study First Received: January 17, 2008

Last Updated: February 20, 2017

Estimated Primary Completion Date: January 2011

 

Primary Outcome Measures:

Number of Participants With Partial Response (PR) of Target Lesions|Number of Months of Progression Free Survival (PFS)

Sponsors and Collaborators:

H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc.

Website Link: https://ClinicalTrials.gov/show/NCT00604461

Leave a Reply